85 results
6-K
EX-99.1
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
expected in 2025
Commercial assessment indicates CSU and HS both represent multi-billion-dollar market opportunities, with tremendous patient need
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
response resulting in anti-IgE therapy discontinuation, as confirmed by investigator assessment CSU diagnosis for ≥ 6 months
Page 75 Exploratory … (PRO) Endpoints (all CFB): Global Impression of Change in General Quality of Life related to HS (PGI-C QoL) Global Assessment of Skin Pain (NRS
6-K
EX-99.1
IFRX
InflaRx N.V.
21 Mar 24
Corporate Presentation March 2024
5:00pm
with established endpoints Safety and PK / PD assessment planned for at least 3 different doses Expected catalysts Phase IIa expected to begin by EOY
6-K
EX-99.2
IFRX
InflaRx N.V.
10 Aug 23
Report of Foreign Private Issuer
8:00am
once all ten patients treated with the maximum tolerated dose identified in stage one, are evaluable for the response assessment. We expect these data
6-K
EX-99.3
vaahtr5 csw24bhalt5
10 Aug 23
Report of Foreign Private Issuer
8:00am
F-3
EX-4.3
todpdn00jhdu 1lnsmk
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-5.1
j4nmc6rap
30 Jun 23
Shelf registration (foreign)
4:06pm
F-3
EX-4.2
55fd6yhs
30 Jun 23
Shelf registration (foreign)
4:06pm
6-K
EX-99.2
qg0kw7600i
11 May 23
Current report (foreign)
8:00am
6-K
EX-5.1
culljnoe vx
13 Apr 23
Current report (foreign)
4:01pm
424B5
k52ub1w
13 Apr 23
Prospectus supplement for primary offering
8:48am
424B5
bxr9q
11 Apr 23
Prospectus supplement for primary offering
4:11pm
6-K
EX-99.2
2w30l17
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.4
e112dqejusqkdxv
9 Nov 22
Current report (foreign)
7:52am
6-K
EX-99.3
jqqn9xyz eg
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.2
vj0cvpss kgsn
5 Aug 22
Current report (foreign)
6:07am
6-K
EX-99.1
h3qieprx9z8e
6 Jul 22
InflaRx Receives FDA Fast Track Designation for Treatment of Ulcerative Pyoderma Gangrenosum
8:30am
6-K
EX-99.3
al5p7owkcqe5fv6 zt
12 May 22
Current report (foreign)
8:30am
6-K
EX-99.1
5beox8jo pwyvu
12 May 22
Current report (foreign)
8:30am